Keyword: Nuplazid

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Months after a late-stage loss in schizophrenia, Acadia's Nuplazid is showing promise at improving the negative symptoms of the disease.

Acadia was stung hard after its schizophrenia hopes for Nuplazid fell flat back in late July. Fortunately, dementia-related psychosis shows promise.

With psychosis med Nuplazid facing a DOJ probe and schizophrenia flop, Acadia hopes a new round of TV ads will help court more patients.

Acadia’s Nuplazid is under the gun after prosecutors launched a marketing probe in March. Now the drug has to cope with a trial flop in schizophrenia.

Acadia Pharmaceuticals is taking Parkinson’s disease education on the road in a partnership with the Michael J. Fox Foundation.

Acadia Pharmaceuticals had to defend its Nuplazid safety last year, and now the drugmaker faces a DOJ probe into its marketing.

When doctors first diagnose Parkinson’s patients, their main focus is motor control. And that gives Acadia, maker of Nuplazid, a big job to do.

With an FDA safety review in the rearview mirror, Acadia is back to business on Nuplazid—and launching its first branded ad campaign to boot.

Acadia suffered from a safety controversy this year on its only marketed drug, Nuplazid, but the FDA again endorsed it after another review.